Skip to main content
Erschienen in: Digestive Diseases and Sciences 12/2021

02.01.2021 | Original Article

Low Levels of Fecal Calprotectin 3 Months After Surgery Predict Subsequent Endoscopic Postoperative Remission in Crohn’s Disease

verfasst von: Florian Veyre, Gilles Boschetti, Camille Meunier, Charlotte Cuerq, Claire Gay, Anne-Laure Charlois, Remi Duclaux-Loras, Pauline Danion, Eddy Cotte, Vahan Kepenekian, Anne Mialon, Mathias Faure, Xavier Roblin, Bernard Flourie, Stéphane Nancey

Erschienen in: Digestive Diseases and Sciences | Ausgabe 12/2021

Einloggen, um Zugang zu erhalten

Abstract

Background/Aims

In Crohn’s disease (CD) few data are available on the usefulness of monitoring fecal calprotectin (FC) in the early postoperative setting. We assessed prospectively the accuracy of FC measured 3 months after surgery to predict the risk of endoscopic postoperative recurrence (POR) within 1 year after resection.

Methods

In 55 consecutive CD patients who had undergone ileocolonic resection samples were collected 3 months after surgery for measuring serum CRP and FC. Endoscopic POR was assessed by ileocolonoscopy within 6–12 months (median 7 months). Receiver operating characteristic (ROC) curves were generated to assess accuracy of the markers, to determine the best threshold and to calculate sensitivity, specificity, positive and negative predictive values.

Results

In contrast with median CRP levels, median FC concentrations measured 3 months after surgery were significantly higher in patients who later experienced endoscopic POR (Rutgeerts ≥ i2) compared with those who stayed in endoscopic remission within the following 6–12 months (205 μg/g IQR [106–721] vs. 103 μg/g IQR [60–219], p = 0.008). Area under the ROC curve for FC was 0.71. The best cutoff value of FC to identify patients in subsequent endoscopic remission 3 months after surgery was 65 μg/g (96% sensitivity, 31% specificity, 50% positive and 91% negative predictive values). In multivariate analysis, FC < 65 µg/g at 3 months was the only factor associated with subsequent endoscopic remission.

Conclusion

FC measured 3 months after surgery below 65 μg/g is an accurate marker to identify CD patients who will later stay in endoscopic remission within 1 year after resection.
Literatur
1.
Zurück zum Zitat Bouguen G, Peyrin-Biroulet L. Surgery for adult Crohn’s disease: what is the actual risk? Gut. 2011;60:1178–1181.CrossRef Bouguen G, Peyrin-Biroulet L. Surgery for adult Crohn’s disease: what is the actual risk? Gut. 2011;60:1178–1181.CrossRef
2.
Zurück zum Zitat Buisson A, Chevaux JB, Allen PB, et al. The natural history of postoperative Crohn’s disease recurrence. Aliment Pharmacol Ther. 2012;35:625–633.CrossRef Buisson A, Chevaux JB, Allen PB, et al. The natural history of postoperative Crohn’s disease recurrence. Aliment Pharmacol Ther. 2012;35:625–633.CrossRef
3.
Zurück zum Zitat De Cruz P, Kamm MA, Hamilton AL, et al. Efficacy of thiopurines and adalimumab in preventing Crohn’s disease recurrence in high risk patients—a POCER study analysis. Aliment Pharmacol Ther. 2015;42:867–879.CrossRef De Cruz P, Kamm MA, Hamilton AL, et al. Efficacy of thiopurines and adalimumab in preventing Crohn’s disease recurrence in high risk patients—a POCER study analysis. Aliment Pharmacol Ther. 2015;42:867–879.CrossRef
4.
Zurück zum Zitat De Cruz P, Kamm MA, Hamilton AM, et al. Crohn’s disease management after intestinal resection: a randomised trial. Lancet. 2015;385:1406–1417.CrossRef De Cruz P, Kamm MA, Hamilton AM, et al. Crohn’s disease management after intestinal resection: a randomised trial. Lancet. 2015;385:1406–1417.CrossRef
5.
Zurück zum Zitat Rutgeerts P, Geboes K, Vantrappen G, et al. Predictability of the postoperative course of Crohn’s disease. Gastroenterology. 1990;99:956–963.CrossRef Rutgeerts P, Geboes K, Vantrappen G, et al. Predictability of the postoperative course of Crohn’s disease. Gastroenterology. 1990;99:956–963.CrossRef
6.
Zurück zum Zitat Gionchetti P, Dignass A, Danese S, et al. 3rd European evidence-based consensus on the diagnosis and management of Crohn’s disease 2016: part 2: Surgical management and special situations. J Crohn’s Colitis. 2016;2017:135–149. Gionchetti P, Dignass A, Danese S, et al. 3rd European evidence-based consensus on the diagnosis and management of Crohn’s disease 2016: part 2: Surgical management and special situations. J Crohn’s Colitis. 2016;2017:135–149.
7.
Zurück zum Zitat Buisson A, Gonzalez F, Poullenot F, et al. Comparative acceptability and perceived clinical utility of monitoring tools: a nationwide survey of patients with inflammatory bowel disease. Inflamm Bowel Dis. 2017;23:1425–1433.CrossRef Buisson A, Gonzalez F, Poullenot F, et al. Comparative acceptability and perceived clinical utility of monitoring tools: a nationwide survey of patients with inflammatory bowel disease. Inflamm Bowel Dis. 2017;23:1425–1433.CrossRef
8.
Zurück zum Zitat Lin JF, Chen JM, Zuo JH, et al. Metaanalysis: fecal calprotectin for assessment of inflammatory bowel disease activity. Inflamm Bowel Dis. 2014;20:1407–1415.CrossRef Lin JF, Chen JM, Zuo JH, et al. Metaanalysis: fecal calprotectin for assessment of inflammatory bowel disease activity. Inflamm Bowel Dis. 2014;20:1407–1415.CrossRef
9.
Zurück zum Zitat Mosli MH, Zou G, Garg SK, et al. C-reactive protein, fecal calprotectin, and stool lactoferrin for detection of endoscopic activity in symptomatic inflammatory bowel disease patients: a systematic review and metaanalysis. Am J Gastroenterol. 2015;110:802–819.CrossRef Mosli MH, Zou G, Garg SK, et al. C-reactive protein, fecal calprotectin, and stool lactoferrin for detection of endoscopic activity in symptomatic inflammatory bowel disease patients: a systematic review and metaanalysis. Am J Gastroenterol. 2015;110:802–819.CrossRef
10.
Zurück zum Zitat Nancey S, Boschetti G, Moussata D, et al. Neopterin is a novel reliable fecal marker as acccurate as calprotectin for predicting endoscopic disease activity in patients with inflammatory bowel diseases. Inflamm Bowel Dis. 2013;19:1043–1052.CrossRef Nancey S, Boschetti G, Moussata D, et al. Neopterin is a novel reliable fecal marker as acccurate as calprotectin for predicting endoscopic disease activity in patients with inflammatory bowel diseases. Inflamm Bowel Dis. 2013;19:1043–1052.CrossRef
11.
Zurück zum Zitat D’Haens G, Ferrante M, Vermeire S, et al. Fecal calprotectin is a surrogate marker for endoscopic lesions in inflammatoruy bowel disease. Inflamm Bowel Dis. 2012;18:2218–2224.CrossRef D’Haens G, Ferrante M, Vermeire S, et al. Fecal calprotectin is a surrogate marker for endoscopic lesions in inflammatoruy bowel disease. Inflamm Bowel Dis. 2012;18:2218–2224.CrossRef
12.
Zurück zum Zitat Lobaton T, Lopez-Garcia A, Rodriguez-Moranta F, et al. A new rapid test for fecal calprotectin predicts endoscopic remission and postoperative recurrence in Crohn’s disease. J Crohn’s Colitis. 2013;7:641–651.CrossRef Lobaton T, Lopez-Garcia A, Rodriguez-Moranta F, et al. A new rapid test for fecal calprotectin predicts endoscopic remission and postoperative recurrence in Crohn’s disease. J Crohn’s Colitis. 2013;7:641–651.CrossRef
13.
Zurück zum Zitat Yamamoto T, Shiraki M, Bamba T, et al. Faecal calprotectin and lactoferrin as markers for monitoring disease activity and predicting clinical recurrence in patients with Crohn’s disease after ileocolonic resection: a prospective pilot study. United Eur Gastroenterol J. 2013;1:368–374.CrossRef Yamamoto T, Shiraki M, Bamba T, et al. Faecal calprotectin and lactoferrin as markers for monitoring disease activity and predicting clinical recurrence in patients with Crohn’s disease after ileocolonic resection: a prospective pilot study. United Eur Gastroenterol J. 2013;1:368–374.CrossRef
14.
Zurück zum Zitat Lasson A, Strid H, Ohman L, et al. Fecal calprotectin one year after ileocaecal resection for Crohn’s disease—a comparison with findings at ileocolonoscopy. J Crohn’s Colitis. 2014;8:789–795.CrossRef Lasson A, Strid H, Ohman L, et al. Fecal calprotectin one year after ileocaecal resection for Crohn’s disease—a comparison with findings at ileocolonoscopy. J Crohn’s Colitis. 2014;8:789–795.CrossRef
15.
Zurück zum Zitat Wright EK, Kamm MA, de Cruz P, et al. Measurement of fecal calprotectin improves monitoring and detection of recurrence of Crohn’s disease after surgery. Gastroenterology. 2015;148:938–947.CrossRef Wright EK, Kamm MA, de Cruz P, et al. Measurement of fecal calprotectin improves monitoring and detection of recurrence of Crohn’s disease after surgery. Gastroenterology. 2015;148:938–947.CrossRef
16.
Zurück zum Zitat Boschetti G, Laidet M, Moussata D, et al. Levels of fecal calprotectin are associated with the severity of postoperative endoscopic recurrence in asymptomatic patients with Crohn’s disease. Am J Gastroenterol. 2015;110:865–872.CrossRef Boschetti G, Laidet M, Moussata D, et al. Levels of fecal calprotectin are associated with the severity of postoperative endoscopic recurrence in asymptomatic patients with Crohn’s disease. Am J Gastroenterol. 2015;110:865–872.CrossRef
17.
Zurück zum Zitat Garcia-Planella E, Manosa M, Cabré E, et al. Fecal calprotectin levels are closely correlated with the absence of relevant mucosal lesions in postoperative Crohn’s disease. Inflamm Bowel Dis. 2016;22:2879–2885.CrossRef Garcia-Planella E, Manosa M, Cabré E, et al. Fecal calprotectin levels are closely correlated with the absence of relevant mucosal lesions in postoperative Crohn’s disease. Inflamm Bowel Dis. 2016;22:2879–2885.CrossRef
18.
Zurück zum Zitat Lopes S, Andrade P, Afonso J, et al. Correlation between calprotectin and modified Rutgeerts score. Inflamm Bowel Dis. 2016;22:2173–2181.CrossRef Lopes S, Andrade P, Afonso J, et al. Correlation between calprotectin and modified Rutgeerts score. Inflamm Bowel Dis. 2016;22:2173–2181.CrossRef
19.
Zurück zum Zitat Schoepfer AM, Lewis JD. Serial fecal calprotectin measurements to detect endoscopic recurrence in postoperative Crohn’s disease: is colonoscopic surveillance no longer needed? Gastroenterology. 2015;148:889–892.CrossRef Schoepfer AM, Lewis JD. Serial fecal calprotectin measurements to detect endoscopic recurrence in postoperative Crohn’s disease: is colonoscopic surveillance no longer needed? Gastroenterology. 2015;148:889–892.CrossRef
20.
Zurück zum Zitat Qiu Y, Mao R, Chen BL, et al. Fecal calprotectin for evaluating postoperative recurrence of Crohn’s disease: a meta-analysis of prospective studies. Inflamm Bowel Dis. 2015;21:315–322.CrossRef Qiu Y, Mao R, Chen BL, et al. Fecal calprotectin for evaluating postoperative recurrence of Crohn’s disease: a meta-analysis of prospective studies. Inflamm Bowel Dis. 2015;21:315–322.CrossRef
21.
Zurück zum Zitat Tham YS, Yung DE, Fay S, et al. Fecal calprotectin for detection of postoperative endoscopic recurrence in Crohn’s disease: systematic review and meta-analysis. Ther Adv Gastroenterol. 2018;11:1–12.CrossRef Tham YS, Yung DE, Fay S, et al. Fecal calprotectin for detection of postoperative endoscopic recurrence in Crohn’s disease: systematic review and meta-analysis. Ther Adv Gastroenterol. 2018;11:1–12.CrossRef
22.
Zurück zum Zitat Lamb CA, Mohiuddin MK, Gicquel J, et al. Fecal calprotectin or lactoferrin can identify postoperative recurrence in Crohn’s disease. Br J Surg. 2009;96:663–674.CrossRef Lamb CA, Mohiuddin MK, Gicquel J, et al. Fecal calprotectin or lactoferrin can identify postoperative recurrence in Crohn’s disease. Br J Surg. 2009;96:663–674.CrossRef
23.
Zurück zum Zitat Sorrentino D, Terrosu G, Paviotti A, et al. Early diagnosis and treatment of postoperative endoscopic recurrence of Crohn’s disease: partial benefit by infliximab—a pilot study. Dig Dis Sci. 2012;57:1341–1348.CrossRef Sorrentino D, Terrosu G, Paviotti A, et al. Early diagnosis and treatment of postoperative endoscopic recurrence of Crohn’s disease: partial benefit by infliximab—a pilot study. Dig Dis Sci. 2012;57:1341–1348.CrossRef
24.
Zurück zum Zitat Cerrillo E, Moret I, Iborra M, et al. A nomogram combining fecal calprotectin levels and plasma cytokine profiles for individual prediction of postoperative Crohn’s disease recurrence. Inflamm Bowel Dis. 2019;25:1681–1691.CrossRef Cerrillo E, Moret I, Iborra M, et al. A nomogram combining fecal calprotectin levels and plasma cytokine profiles for individual prediction of postoperative Crohn’s disease recurrence. Inflamm Bowel Dis. 2019;25:1681–1691.CrossRef
25.
Zurück zum Zitat Orlando A, Modesto I, Castiglione F, et al. The role of calprotectin in predicting endoscopic post-surgical recurrence in asymptomatic Crohn’s disease: a comparison with ultrasound. European Rev Med Pharmacol Sci. 2006;10:17–22. Orlando A, Modesto I, Castiglione F, et al. The role of calprotectin in predicting endoscopic post-surgical recurrence in asymptomatic Crohn’s disease: a comparison with ultrasound. European Rev Med Pharmacol Sci. 2006;10:17–22.
26.
Zurück zum Zitat Boube M, Laharie D, Nancey S, et al. Variation of fecal calprotectin level within the first three months after bowel resection is predictive of endoscopic postoperative recurrence in Crohn’s disease. Dig Liver Dis 2020 (in press). Boube M, Laharie D, Nancey S, et al. Variation of fecal calprotectin level within the first three months after bowel resection is predictive of endoscopic postoperative recurrence in Crohn’s disease. Dig Liver Dis 2020 (in press).
27.
Zurück zum Zitat Tytgat GNJ, Mulder CJJ, Brummelkamp WH. Endoscopic lesions in Crohn’s disease early after ileocecal resection. Endoscopy. 1988;20:260–262.CrossRef Tytgat GNJ, Mulder CJJ, Brummelkamp WH. Endoscopic lesions in Crohn’s disease early after ileocecal resection. Endoscopy. 1988;20:260–262.CrossRef
28.
Zurück zum Zitat Olaison G, Smedh K, Sjödahl R. Natural course of Crohn’s disease after ileocolic resection: endoscopically visualised ileal ulcers preceeding symptoms. Gut. 1992;33:331–335.CrossRef Olaison G, Smedh K, Sjödahl R. Natural course of Crohn’s disease after ileocolic resection: endoscopically visualised ileal ulcers preceeding symptoms. Gut. 1992;33:331–335.CrossRef
29.
Zurück zum Zitat Mowatt C, Arnott I, Cahill A, et al. Mercaptopurine versus placebo to prevent recurrence of Crohn’s disease after surgical resection (TOPPIC): a multicenter, double-blind, randomized controlled trial. Lancet Gastroenterol Hepatol. 2016;1:273–282.CrossRef Mowatt C, Arnott I, Cahill A, et al. Mercaptopurine versus placebo to prevent recurrence of Crohn’s disease after surgical resection (TOPPIC): a multicenter, double-blind, randomized controlled trial. Lancet Gastroenterol Hepatol. 2016;1:273–282.CrossRef
30.
Zurück zum Zitat D’Amico F, Nancey S, Danese S, et al. A practical guide for fecal calprotectin dosage: myths and realities. J Crohns Colitis 2020 (in press). D’Amico F, Nancey S, Danese S, et al. A practical guide for fecal calprotectin dosage: myths and realities. J Crohns Colitis 2020 (in press).
Metadaten
Titel
Low Levels of Fecal Calprotectin 3 Months After Surgery Predict Subsequent Endoscopic Postoperative Remission in Crohn’s Disease
verfasst von
Florian Veyre
Gilles Boschetti
Camille Meunier
Charlotte Cuerq
Claire Gay
Anne-Laure Charlois
Remi Duclaux-Loras
Pauline Danion
Eddy Cotte
Vahan Kepenekian
Anne Mialon
Mathias Faure
Xavier Roblin
Bernard Flourie
Stéphane Nancey
Publikationsdatum
02.01.2021
Verlag
Springer US
Erschienen in
Digestive Diseases and Sciences / Ausgabe 12/2021
Print ISSN: 0163-2116
Elektronische ISSN: 1573-2568
DOI
https://doi.org/10.1007/s10620-020-06751-z

Weitere Artikel der Ausgabe 12/2021

Digestive Diseases and Sciences 12/2021 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.